Galapagos NV ADR
$ 33.87
0.30%
23 Feb - close price
- Market Cap 2,250,004,000 USD
- Current Price $ 33.87
- High / Low $ 34.06 / 33.40
- Stock P/E N/A
- Book Value 43.75
- EPS -8.00
- Next Earning Report f
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.05 %
- ROE -0.17 %
- 52 Week High 37.78
- 52 Week Low 22.59
About
Galapagos NV, a clinical-stage biotechnology company, discovers, develops and markets several small molecule drugs. The company is headquartered in Mechelen, Belgium.
Analyst Target Price
$27.44
Quarterly Earnings
| Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-02-24 | 2025-11-05 | 2025-07-24 | 2025-04-30 | 2025-02-12 | 2024-10-31 | 2024-08-01 | 2024-05-02 | 2024-02-22 | 2023-11-02 | 2023-08-03 | 2023-05-04 |
| Reported EPS | 0 | -3.54 | -1.58 | -2.45 | 0.3023 | -0.83 | 0.14 | 1.4 | 2.39 | 0.39 | 0.08 | 0.3852 |
| Estimated EPS | -0.2039 | -0.3529 | -0.2283 | -0.18 | 0.28 | -0.29 | -0.04 | -0.13 | -1.18 | -0.62 | -0.7 | -0.87 |
| Surprise | 0.2039 | -3.1871 | -1.3517 | -2.27 | 0.0223 | -0.54 | 0.18 | 1.53 | 3.57 | 1.01 | 0.78 | 1.2552 |
| Surprise Percentage | 100% | -903.117% | -592.0718% | -1261.1111% | 7.9643% | -186.2069% | 450% | 1176.9231% | 302.5424% | 162.9032% | 111.4286% | 144.2759% |
Next Quarterly Earnings
| Feb 2026 | |
|---|---|
| Reported Date | f |
| Fiscal Date Ending | o |
| Estimated EPS | r |
| Currency | m |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: GLPG
2026-02-24 00:25:40
Galapagos reported a significant turnaround in 2025, moving from an operating loss to a profit of €295.1 million, largely due to a €1.069 billion deferred income release from a collaboration. The company is strategically exiting its cell therapy business, streamlining its workforce, and focusing on immunology with promising Phase 2 data for its TYK2 inhibitor GLPG3667, while also exploring partnership opportunities. This strategic repositioning aims for business development-led growth and cash flow neutrality by late 2026.
2026-02-21 12:57:57
A long-term safety analysis of the JAK inhibitor filgotinib for moderate-to-severe rheumatoid arthritis revealed potential dose-dependent risks for herpes zoster, malignancies, and all-cause mortality in patients aged 65 and older. While most other treatment-emergent adverse events remained stable over time, the study highlighted that older patients might benefit from the 100mg dose due to lower incidences of certain adverse events compared to the 200mg dose. This analysis supports updated product characteristics recommending filgotinib's use in older patients only when alternative treatments are unsuitable.
2026-02-20 11:29:44
Galapagos NV is anticipated to report a loss of 25 cents per share, according to a recent earnings preview. This financial outlook highlights the company's expected performance in its upcoming earnings report. The information is provided by Refinitiv.
2026-02-20 00:57:19
Galapagos has appointed Dr. Paulo Fontoura as a Non-Executive Independent Director, effective February 9, 2026, succeeding Dr. Susanne Schaffert. Dr. Fontoura brings extensive pharmaceutical leadership experience from Roche, and his appointment is expected to bolster Galapagos' strategic oversight as it advances innovative medicines and business development. Analysts currently rate GLPG stock as a Sell with a $22.00 price target, while TipRanks’ AI Analyst, Spark, assigns a Neutral rating due to challenging financial and operational landscapes despite a strong cash position.
2026-02-19 22:01:00
Galapagos NV announced the appointment of Dr. Paulo Fontoura as a Non-Executive Independent Director to its Board of Directors, effective February 9, 2026. Dr. Fontoura brings extensive experience in clinical development across various therapeutic areas, having previously served as SVP and Global Head at Roche and currently as Chief Medical Officer at Xaira. He replaces Dr. Susanne Schaffert and is expected to provide strategic guidance as Galapagos focuses on advancing innovative medicines and pursuing transformative business development opportunities.
2026-02-19 21:27:19
Galapagos NV has appointed Dr. Paulo Fontoura as a Non-Executive Independent Director to its Board, effective February 9, 2026. Dr. Fontoura brings 20 years of pharmaceutical industry experience across various therapeutic areas and replaces Dr. Susanne Schaffert. This appointment is expected to bolster the company's strategic guidance as it pursues transformative business development opportunities and advances innovative medicines.
